JAK2 and acute lymphoblastic leukemia: We therefore conclude that the consistent loss of Pax5 in Pax5Jak2/+ B‐ALL tumors allows Pax5‐Jak2 to bind to its target sites in the genome, which strongly argues for a nuclear function of Pax5‐Jak2.